Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16293342 | 0.92 | HPGD (0.45) | HPGDEPHX1KDM4EPKMGPR119 | |
| SCHEMBL16293179 | 0.89 | RECQL (0.54) | HPGDKDM4EPKMGPR119RECQL | |
| SCHEMBL6152184 | 0.85 | HPGD (0.56) | HPGDEPHX1KDM4EPKMGPR119 | |
| SCHEMBL27121409 | 0.84 | DDB1 (0.41) | HPGD | |
| SCHEMBL21998064 | 0.83 | HPGD (0.48) | HPGDEPHX1KDM4EPKMGPR119 | |
| SCHEMBL3159388 | 0.83 | HPGD (0.58) | HPGDEPHX1KDM4EPKMGPR119 | |
| SCHEMBL796239 | 0.83 | HPGD (0.53) | HPGDEPHX1KDM4EPKMGPR119 | |
| SCHEMBL30230188 | 0.82 | KDM4E (0.49) | HPGDEPHX1KDM4EPKMGPR119 | |
| SCHEMBL30102395 | 0.82 | HPGD (0.47) | HPGDEPHX1KDM4EPKMGPR119 | |
| SCHEMBL14395365 | 0.82 | GPR119 (0.51) | HPGDEPHX1KDM4EPKMGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152634-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | XENTION LTD (GB) | 2016-06-02 | — | — | US | disclosed |
| US-9290511-B2 | Thieno-pyrimidines, useful as potassium channel inhibitors | XENTION LIMITED (GB) | 2016-03-22 | — | — | US | disclosed |
| US-20140371203-A1 | Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors | XENTION LIMITED (GB) | 2014-12-18 | — | — | US | disclosed |
| US-20140357662-A1 | THIENO (2,3 - C) PYRAZOLES FOR USE AS POTASSIUM CHANNEL INHIBITORS | XENTION LIMITED (GB) | 2014-12-04 | — | — | US | disclosed |
| EP-2780343-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | Xention Limited (GB) | 2014-09-24 | — | — | EP | disclosed |
| EP-2780344-A1 | THIENO [2, 3 - C]PYRAZOLES FOR USE AS POTASSIUM CHANNEL INHIBITORS | Xention Limited (GB) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013072694-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | XENTION LIMITED (GB) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013072693-A1 | THIENO [2, 3 - C] PYRAZOLES FOR USE AS POTASSIUM CHANNEL INHIBITORS | XENTION LIMITED (GB) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371203-A1 | Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors | KCNA3, KCNJ1, KCNJ11 | HPGD 2232/4885EPHX1 1356/4885KDM4E 897/4885 |
| US-20160152634-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | KCNA3, KCNJ1, KCNJ11 | HPGD 2105/4885EPHX1 1247/4885KDM4E 809/4885 |
| US-20140357662-A1 | THIENO (2,3 - C) PYRAZOLES FOR USE AS POTASSIUM CHANNEL INHIBITORS | KCNA3, KCNK3, KCNJ1 | HPGD 2559/4885EPHX1 1400/4885KDM4E 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.